...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy.
【24h】

Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy.

机译：仅前列腺癌近距离放射治疗后的无故障生存期：与外部放射线放射疗法的比较。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND PURPOSE: To compare failure free survival (FFS) for brachytherapy (BT) alone and external beam radiotherapy (EBXRT) alone. MATERIALS AND METHODS: Between 12/88 and 12/95, 1527 and 695 T(1) or T(2) Nx-No Mo prostate cancer patients (from the Arizona Oncology Services database) were treated with either EBXRT or BT, respectively. The median age was 74 years. Median follow-up for EBXRT and BT patients was 41.3 and 51.3 months, respectively. RESULTS: Overall FFS at 5 years for EBXRT and BT were 69 and 71%, respectively (P=0.91). No significant difference in FFS at 5 years was observed between EBXRT and BT for either T(1) (78 vs. 83%, P=0.47) or T(2) (67 vs. 67%, P=0.89) tumours. Superior outcomes for Gleason 8-10 lesions treated with EBXRT vs. BT (5 years FFS 52 vs. 28%, P=0.04) were observed; outcomes for lower grade lesions when analysed by Gleason score alone did not significantly differ according to treatment received. Patients with initial PSA values 10-20 ng/dl had an improved FFS with EBXRT vs. BT (70 vs. 53%, P=0.001); outcomes for patients with initial PSA ranges 0-4 ng/dl, >4-10 ng/dl and >20 ng/dl did not differ significantly with treatment received. CONCLUSIONS: EBXRT and BT appear to be equally efficacious for low-risk patients having T(1)/T(2) disease with Gleason scores <6 and PSA <10 ng/dl. Patients with Gleason scores 8-10 or PSA >10 ng/dl-<20 ng/dl) appear to fare worse with BT alone compared with EBXRT. Neither EBXRT nor BT were particularly effective for patients with a presenting PSA >20 ng/dl.
机译：背景与目的：比较单独近距离放射治疗（BT）和单独外部束放射治疗（EBXRT）的无失败生存率（FFS）。材料与方法：在12/88与12 / 95、1527与695之间，分别用EBXRT或BT治疗T（1）或T（2）Nx-No Mo前列腺癌患者（来自Arizona Oncology Services数据库）。中位年龄为74岁。 EBXRT和BT患者的中位随访时间分别为41.3和51.3个月。结果：EBXRT和BT的5年总FFS分别为69％和71％（P = 0.91）。对于T（1）（78 vs. 83％，P = 0.47）或T（2）（67 vs. 67％，P = 0.89）肿瘤，EBXRT和BT在5年时未观察到FFS的显着差异。观察到用EBXRT与BT治疗的Gleason 8-10病变的结局更好（5年FFS 52 vs. 28％，P = 0.04）。仅根据格里森评分进行分析时，较低级别病变的预后根据所接受的治疗没有显着差异。 PSA初始值为10-20 ng / dl的患者，EBXRT与BT相比，FFS有所改善（70％对53％，P = 0.001）。初始PSA范围为0-4 ng / dl，> 4-10 ng / dl和> 20 ng / dl的患者的预后与接受的治疗无显着差异。结论：EBXRT和BT对于Gleason评分<6和PSA <10 ng / dl的T（1）/ T（2）疾病低危患者似乎同样有效。 Gleason评分为8-10或PSA> 10 ng / dl- <20 ng / dl的患者，与EBXRT相比，单独使用BT的情况似乎更糟。 EBXRT和BT都不对PSA> 20 ng / dl的患者特别有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号